NASDAQ:IOBT IO Biotech Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.50 -0.17 (-3.64%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$4.13▼$4.5850-Day Range$3.79▼$7.9452-Week Range$3.56▼$17.88Volume2,491 shsAverage Volume41,295 shsMarket Capitalization$129.67 millionP/E RatioN/ADividend YieldN/APrice Target$20.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IO Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside355.6% Upside$20.50 Price TargetShort InterestHealthy0.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.51) to ($2.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.01 out of 5 starsMedical Sector495th out of 1,427 stocksPharmaceutical Preparations Industry234th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, IO Biotech has a forecasted upside of 355.6% from its current price of $4.50.Amount of Analyst CoverageIO Biotech has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.03% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IO Biotech has recently increased by 106.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 2.7 News and Social Media Coverage News SentimentIO Biotech has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IO Biotech this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IOBT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders11.60% of the stock of IO Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.20% of the stock of IO Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to grow in the coming year, from ($2.51) to ($2.27) per share.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address About IO Biotech (NASDAQ:IOBT) StockIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More IOBT Stock News HeadlinesJune 6, 2022 | finance.yahoo.comIO Biotech to Participate in the 2022 BIO International ConventionMay 26, 2022 | finance.yahoo.comIO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022May 23, 2022 | finance.yahoo.comIO Biotech to Participate in the Jefferies Healthcare ConferenceMay 18, 2022 | finance.yahoo.comIO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced MelanomaMay 16, 2022 | finance.yahoo.comIO Biotech Announces First Quarter Results for 2022May 8, 2022 | finance.yahoo.comWe're Not Very Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn RateApril 22, 2022 | finance.yahoo.comIO Biotech Hosting Key Opinion Leader Webinar SeriesApril 12, 2022 | seekingalpha.comIO Biotech begins mid-stage trial of NSCLC candidate IO102-IO103April 12, 2022 | finance.yahoo.comIO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket TrialApril 11, 2022 | finance.yahoo.comIO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In MelanomaApril 10, 2022 | investing.comIO Biotech Inc (IOBT)April 8, 2022 | seekingalpha.comIO Biotech posts positive data from metastatic melanoma therapy trialApril 8, 2022 | finance.yahoo.comIO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual MeetingMarch 31, 2022 | seekingalpha.comIO Biotech reports FY resultsMarch 9, 2022 | seekingalpha.comSUNW, CEI and HNRG among mid-day moversMarch 8, 2022 | finance.yahoo.comIO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022March 3, 2022 | finance.yahoo.comIO Biotech Announces Appointment of David V. Smith to its Board of DirectorsFebruary 7, 2022 | finance.yahoo.comWhat Kind Of Investors Own Most Of IO Biotech, Inc. (NASDAQ:IOBT)?February 5, 2022 | nasdaq.comCould The IO Biotech, Inc. (NASDAQ:IOBT) Ownership Structure Tell Us Something Useful?December 9, 2021 | finance.yahoo.comIO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature MedicineDecember 6, 2021 | finance.yahoo.comIO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket TrialDecember 3, 2021 | nasdaq.comIO Biotech Trading 21% HigherDecember 2, 2021 | realmoney.thestreet.comIO Biotech, Inc. (IOBT)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees19Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$20.50 High Stock Price Forecast$21.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+355.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio30.99 Quick Ratio30.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book0.61Miscellaneous Outstanding Shares28,815,000Free Float25,472,000Market Cap$129.67 million OptionableNot Optionable BetaN/A IO Biotech Frequently Asked Questions Should I buy or sell IO Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IO Biotech stock. View analyst ratings for IO Biotech or view top-rated stocks. What is IO Biotech's stock price forecast for 2022? 3 Wall Street analysts have issued 12 month price targets for IO Biotech's shares. Their IOBT stock forecasts range from $20.00 to $21.00. On average, they expect IO Biotech's stock price to reach $20.50 in the next year. This suggests a possible upside of 355.6% from the stock's current price. View analysts' price targets for IO Biotech or view top-rated stocks among Wall Street analysts. How has IO Biotech's stock performed in 2022? IO Biotech's stock was trading at $6.40 at the beginning of 2022. Since then, IOBT stock has decreased by 29.7% and is now trading at $4.50. View the best growth stocks for 2022 here. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) released its earnings results on Monday, May, 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.06. View IO Biotech's earnings history. Who are IO Biotech's key executives? IO Biotech's management team includes the following people: Dr. Mai-Britt Zocca Ph.D., Founder, Pres, CEO, Principal Financial Officer & Director (Age 54, Pay $514.12k)Dr. Muhammad Al-Hajj Ph.D., Chief Scientific Officer (Age 51, Pay $486.63k)Dr. Eva Ehrnrooth M.D., Ph.D., Chief Medical Officer (Age 58, Pay $443.5k)Prof. Inge Marie Svane M.D., Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen Ph.D., Founder & Scientific AdvisorAnders Ljungqvist, FounderProf. Per Thor Straten, FounderMr. Brian Burkavage, VP of Fin. & Chief Accounting Officer (Age 39)Mr. Mikkel Dybkjær, VP of Corp. Fin. (Age 50)Dan Mannix, Sr. VP of Regulatory Affairs Who are some of IO Biotech's key competitors? Some companies that are related to IO Biotech include Bicycle Therapeutics (BCYC), GH Research (GHRS), Pharming Group (PHAR), 2seventy bio (TSVT), Radius Health (RDUS), Janux Therapeutics (JANX), Celularity (CELU), Altimmune (ALT), Centessa Pharmaceuticals (CNTA), Calliditas Therapeutics AB (publ) (CALT), Imago BioSciences (IMGO), Cara Therapeutics (CARA), COMPASS Pathways (CMPS), Amryt Pharma (AMYT) and Mersana Therapeutics (MRSN). View all of IOBT's competitors. When did IO Biotech IPO? (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share. What is IO Biotech's stock symbol? IO Biotech trades on the NASDAQ under the ticker symbol "IOBT." How do I buy shares of IO Biotech? Shares of IOBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IO Biotech's stock price today? One share of IOBT stock can currently be purchased for approximately $4.50. How much money does IO Biotech make? IO Biotech (NASDAQ:IOBT) has a market capitalization of $129.67 million. How many employees does IO Biotech have? IO Biotech employs 19 workers across the globe. How can I contact IO Biotech? The official website for IO Biotech is www.iobiotech.com. The company can be reached via phone at 45-7070-2980. This page (NASDAQ:IOBT) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
